A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Everolimus (Primary) ; Giredestrant (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Ribociclib (Primary) ; Samuraciclib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms MORPHEUS BC
- Sponsors Roche
- 04 Jun 2024 Interim results assessing safety and efficacy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 24 Oct 2023 Interim results (n=32; As of 17 May 2022) assessing the efficacy of giredestrant plus ipatasertib in patients with ER+, HER2-negative, locally advanced/metastatic breast cancer, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Interim results at week 16 presented at the 59th Annual Meeting of the American Society of Clinical Oncology